Continental Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Continental Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,000	Closed	-$474K	–	47
2024 Q1	$474K	Sell	5,000 -25,000	-83%	-$2.32M	0.19%	43
2023 Q4	$2.68M	Buy	30,000 +20,000	+200%	+$1.49M	1.05%	30
2023 Q3	$730K	Buy	10,000 +5,000	+100%	+$399K	0.39%	41
2023 Q2	$416K	Hold	5,000	–	–	0.19%	48
2023 Q1	$381K	Sell	5,000 -11,700	-70%	-$971K	0.2%	48
2022 Q4	$1.39M	Sell	16,700 -9,000	-35%	-$729K	0.73%	44
2022 Q3	$2.04M	Sell	25,700 -8,000	-24%	-$674K	1.2%	35
2022 Q2	$2.5M	Buy	33,700 +22,700	+206%	+$1.7M	1.51%	25
2022 Q1	$989K	Buy	+11,000	New	+$1.02M	0.49%	47

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Continental Advisors's XBI Position: Q2 2026 in Review

Continental Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 38% in Q2 2026, selling an estimated $1.42M and leaving 17,200 shares worth $2.72M. The position accounts for 1.15% of the portfolio, ranked #27.

Continental Advisors first reported a position in XBI in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.82M in Q4 2022. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Continental Advisors held 17,200 shares of State Street SPDR S&P Biotech ETF worth $2.72M as of Q2 2026.
Continental Advisors sold 10,500 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.42M.
State Street SPDR S&P Biotech ETF made up 1.15% of Continental Advisors's portfolio in Q2 2026, its #27 holding.
Continental Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 18 quarters since.
Continental Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.82M in Q4 2022.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Continental Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.